Completion <i>vs</i> . early discontinuation of chemotherapy and the impact on 5‐year all‐cause mortality in women treated for early‐stage breast cancer from 2015 to 2020: A cohort study using a target trial emulation approach
Patients who completed greater than or equal to six cycles showed improved OS compared with those who discontinued before receiving six cycles. These findings support the identification and pre-emptive management of patients at high risk of discontinuing chemotherapy prematurely, to maximize treatment benefit.
Authors
- Kenneth K. C. Man (ORCID: https://orcid.org/0000-0001-8645-1942)
- L. Wei
- Luke Steventon (ORCID: https://orcid.org/0009-0004-6759-4701)
- Chiara Creed
- Diego Ottaviani
- R. Roylance
- Chengsheng Ju
- Alec Wisner
- Pinkie Chambers
- Michal Sladkowski
Institutions
- University of North Carolina at Chapel Hill (US)
- Cleveland Clinic (US)
- University College London Hospitals NHS Foundation Trust (GB)
- Cancer Research UK (GB)
- Centre for Higher Education (DE)
- York Teaching Hospital NHS Foundation Trust (GB)
- CRUK Lung Cancer Centre of Excellence (GB)
- University College London (GB)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2026-03-08
- DOI
- https://doi.org/10.1002/bcp.70488
- Primary Topic
- Global Cancer Incidence and Screening
- Type
- article
- Field-Weighted Citation Impact
- 0.00